Karolinska Development recruits John Öhd to the position of Chief Scientific Officer

STOCKHOLM, SWEDEN – May 18, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has recruited Dr. John Öhd to the role of Chief Scientific Officer. He has a solid scientific background and extensive experience from senior positions in global pharmaceutical companies' research organizations, including AstraZeneca and Shire Pharmaceuticals.

   

John Öhd, M.D., Ph.D., has a broad knowledge and experience of drug development in a number of therapeutic areas, including CNS, cancer and blood diseases. He has worked as a Group Director within AstraZeneca's research organization, Senior Director of Experimental Medicine at Shire Pharmaceutical's facilities in Switzerland and Chief Medical Officer at Medivir. He most recently comes from a position as Chief Medical Officer at Modus Therapeutics.

“We are delighted to welcome John Öhd to the position of Chief Scientific Officer. His solid scientific and medical background will strengthen Karolinska Development in the active work with our portfolio companies and in the evaluation of potential new investments,” says Viktor Drvota, CEO of Karolinska Development.

John Öhd assumes the position of Chief Scientific Officer on a half-time basis on June 1, 2020, allowing for a parallel commitment as CEO of Modus Therapeutics – one of Karolinska Development's portfolio companies. He will report directly to Karolinska Development's CEO and be part of the company's management team.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

Fredrik Järrsten, CFO and deputy CEO, Karolinska Development AB

Phone: +46 70 496 46 28, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

Attachment